|Table of Contents|

Analysis of the incidence and death rate of female reproductive system tumors in China

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 23
Page:
4426-4431
Research Field:
Publishing date:

Info

Title:
Analysis of the incidence and death rate of female reproductive system tumors in China
Author(s):
JIANG Danfeng1; ZHU Mengxiu1; ZHAO Qingjuan2; LI Jiangqiu3; SUN Huixin4
1.Department of Oncology and Hematology,Harbin 242 Hospital，Heilongjiang Harbin 150060,China;2.The Second Department of Oncology,Mudanjiang Cancer Hospital,Heilongjiang Mudanjiang 157009,China;3.Department of Oncology,Harbin First Hospital,Heilongjiang Harbin 150010,China;4.Institute of Cancer Prevention and Treatment,Harbin Medical University,Heilongjiang Harbin 150081,China.
Keywords:
cervical cancer; uterine cancer; ovarian cancer; female reproductive system; incidence; death rate
PACS:
R737.3
DOI:
10.3969/j.issn.1672-4992.2023.23.025
Abstract:
Objective:To understand the prevalence and trend of female reproductive system tumors in China from 1990 to 2019.Methods:The global disease burden database 2019 was used to analyze the incidence and death rate of female reproductive system tumors in different age groups and years,and the incidence and death rate trends of female reproductive system tumors from 1990 to 2019 were analyzed.Results:In 2019,the order of incidence of female reproductive system tumors was cervical cancer(7.72/100 000),uterine cancer(4.69/100 000) and ovarian cancer(3.20/100 000).The death rate order from high to low was cervical cancer(3.76/100 000),ovarian cancer(2.05/100 000) and uterine cancer(0.86/100 000).Cervical cancer began to occur in the 15-year-old age group,uterine cancer in the 20-year-old age group,and ovarian cancer in the 5-year-old age group.In most age groups,the incidence and death rate of cervical cancer was higher than that of uterine cancer and ovarian cancer.The incidence rate of uterine cancer was higher than that of ovarian cancer,but the death rate of ovarian cancer was higher than that of uterine cancer.From 1990 to 2019,no matter the incidence rate or the standardized incidence rate,cervical cancer,uterine cancer and ovarian cancer had an upward trend.The mortality rate of cervical cancer and ovarian cancer increased,but there was no significant change in uterine cancer.After adjusting the age structure,the standardized mortality rate of cervical cancer and uterine cancer showed a downward trend,while the rising trend of ovarian cancer was relatively lower.Compared with the global average,the standardized incidence rate and standardized death rate of cervical cancer,uterine cancer and ovarian cancer in women in China were lower.Conclusion:From 1990 to 2019,the standardized incidence rate of cervical cancer,uterine cancer and ovarian cancer in women in China still showed an upward trend.Although the disease burden of female reproductive system tumors in China was lower than the global average,the population base in China was large,and active preventive measures should continue to be taken to reduce the disease burden of female reproductive system tumors.

References:

[1]FERLAY J,COLOMBET M,SOERJOMATARAM I,et al.Cancer statistics for the year 2020:An overview［J/OL］.Int J Cancer,2021［2021-04-05］.https://pubmed.ncbi.nlm.nih.gov/33818764.DOI:10.1002/ijc.33588.
[2]SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
[3]HE R,ZHU B,LIU J,et al.Women's cancers in China:a spatio-temporal epidemiology analysis［J］.BMC Womens Health,2021,21(1):116.
[4]JIANG X,TANG H,CHEN T.Epidemiology of gynecologic cancers in China［J］.J Gynecol Oncol,2018,29(1):e7.
[5]JIN G,ZOU M,ZHANG Y,et al.Time trends,associations and global burden of intraocular foreign bodies［J］.Br J Ophthalmol,2022,106(3):435-439.
[6]Global Burden of Disease Study 2019.Global burden of 369 diseases and injuries in 204 countries and territories,1990-2019:a systematic analysis for the Global Burden of Disease Study 2019［J］.Lancet,2020,396(10258):1204-1222.
[7]KIM HJ,FAY MP,FEUER EJ,et al.Permutation tests for joinpoint regression with applications to cancer rates［J］.Stat Med,2000,19(3):335-351.
[8]WANG Z,GUO E,YANG B,et al.Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019:Cervical,ovarian and uterine cancer［J］.Gynecol Oncol,2021,163(2):358-363.
[9]WEI M,ZHOU W,BI Y,et al.Rising mortality rate of cervical cancer in younger women in urban China［J］.J Gen Intern Med,2019,34(2):281-284.
[10]ZHAO F,QIAO Y.Cervical cancer prevention in China:a key to cancer control［J］.Lancet,2019,393(10175):969-970.
[11]蔡会龙,原伟光,孙惠昕.全球及我国宫颈癌流行现状及防治策略［J］.临床肿瘤学杂志,2023,28(1):90-93. CAI HL,YUAN WG,SUN HX.Epidemic status and prevention and treatment strategies of cervical cancer worldwide and in China ［J］.Journal of Clinical Oncology,2023,28(1):90-93.
[12]BRAY F,LOOS AH,TOGNAZZO S,et al.Ovarian cancer in Europe:Cross-sectional trends in incidence and mortality in 28 countries,1953-2000［J］.Int J Cancer,2005,113(6):977-990.
[13]孙惠昕,张茂祥,王婉莹，等.癌症筛查与早诊早治的研究进展［J］.现代肿瘤医学,2021,29(18):3287-3290. SUN HX,ZHANG MX,WANG WY,et al.Research progress in cancer screening,early diagnosis and treatment ［J］.Modern Oncology Medicine,2021,29(18):3287-3290.
[14]NESS KK,WOGKSCH MD.Frailty and aging in cancer survivors［J］.Transl Res,2020,221:65-82.

Memo

Memo:
2021年度黑龙江省自然科学基金优秀青年项目（编号：YQ2021H021）
Last Update: 2023-10-31